Pacira Biosciences, Inc. last reported quarterly results on Aug 4, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $192.4 million (+6.2% year over year) and diluted EPS of $0.12. It usually reports 8–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 5, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 6, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 4, 2026
35 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
192
+6.2%
|
5
+196.0%
|
0.12
+209.1%
|
|
Apr 30, 2026
30 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
177
+5.0%
|
3
-39.4%
|
0.07
-30.0%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
197
|
2
-89.8%
|
0.04
-89.0%
|
|
Nov 6, 2025
37 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
180
+6.5%
|
5
+103.8%
|
0.12
+103.9%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
181
+1.7%
|
-5
-125.7%
|
-0.11
-128.2%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
169
+1.1%
|
5
-46.4%
|
0.10
-47.4%
|
|
Jan 10, 2025
10 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
16
-35.5%
|
0.35
-4.1%
|
|
Nov 6, 2024
37 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1396814
- Former names
- Pacira Pharmaceuticals, Inc. (until Apr 9, 2019); PACIRA INC (until Nov 5, 2008); Blue Acquisition Corp (until Apr 16, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.